Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deutenzalutamide plus ADT vs placebo plus ADT in high‑risk biochemical recurrent prostate cancer (Phase III)
CTR20263220Phase 3Active
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deutenzalutamide in prostate adenocarcinoma, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Aug 2026; status: active.
02
Drugs
deutenzalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20263220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263220.